A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have been approved by The United States Food and Drug Administration (FDA). The case-by-case autologous T cell generation setting is largely considered as a pivotal restraining cause for its large-scale clinical us...

Descripción completa

Detalles Bibliográficos
Autores principales: Razeghian, Ehsan, Nasution, Mahyuddin K. M., Rahman, Heshu Sulaiman, Gardanova, Zhanna R., Abdelbasset, Walid Kamal, Aravindhan, Surendar, Bokov, Dmitry O., Suksatan, Wanich, Nakhaei, Pooria, Shariatzadeh, Siavash, Marofi, Faroogh, Yazdanifar, Mahboubeh, Shamlou, Somayeh, Motavalli, Roza, Khiavi, Farhad Motavalli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317439/
https://www.ncbi.nlm.nih.gov/pubmed/34321099
http://dx.doi.org/10.1186/s13287-021-02510-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317439/
https://www.ncbi.nlm.nih.gov/pubmed/34321099
http://dx.doi.org/10.1186/s13287-021-02510-7

Ejemplares similares